Last updated: 4 July 2020 at 1:04pm EST

Fund V, L.P.Omega Fund V Gp... Net Worth




The estimated Net Worth of Fund V, L.P.Omega Fund V Gp... is at least $3.51 millió dollars as of 9 May 2019. Fund Gp owns over 481,000 units of Trevi Therapeutics stock worth over $3,509,246 and over the last 6 years Fund sold TRVI stock worth over $0.

Fund Gp TRVI stock SEC Form 4 insiders trading

Fund has made over 1 trades of the Trevi Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Fund bought 481,000 units of TRVI stock worth $4,810,000 on 9 May 2019.

The largest trade Fund's ever made was buying 481,000 units of Trevi Therapeutics stock on 9 May 2019 worth over $4,810,000. On average, Fund trades about 481,000 units every 0 days since 2019. As of 9 May 2019 Fund still owns at least 1,063,408 units of Trevi Therapeutics stock.

You can see the complete history of Fund Gp stock trades at the bottom of the page.



Insiders trading at Trevi Therapeutics

Over the last 5 years, insiders at Trevi Therapeutics have traded over $2,844,492 worth of Trevi Therapeutics stock and bought 79,366,506 units worth $381,350,992 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Forest Baskett és Scott D Sandell. On average, Trevi Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $3,549,117. The most recent stock trade was executed by Jennifer L Good on 6 September 2024, trading 6,059 units of TRVI stock currently worth $8,664.



What does Trevi Therapeutics do?

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.



What does Trevi Therapeutics's logo look like?

Trevi Therapeutics, Inc. logo

Complete history of Fund Gp stock trades at Trevi Therapeutics

Dátum
#
Cég
Az érdekelt
Trans.
Tranzakció
Részvények száma Ár per részvény Teljes ár Részvények szíma után Forrás
9 May 2019 Fund V, L.P.Omega Fund V Gp...
Megvenni 481,000 $10.00 $4,810,000
9 May 2019
1,063,408


Trevi Therapeutics executives and stock owners

Trevi Therapeutics executives and other stock owners filed with the SEC include: